Table 4 Adverse events recorded for the MSC-treated and placebo-treated patients.
Items | MSC group | Placebo group |
|---|---|---|
Adverse events | ||
Number of patients | 3 (10.3) | 13 (44.8) |
Disturbance of consciousness | 0 | 2 (6.9) |
Urinary tract infection | 0 | 1 (3.4) |
Headache | 0 | 1 (3.4) |
Palpitations | 1 (3.4%) | 3 (10.3) |
Fever | 0 | 3 (10.3) |
Diarrhea/bloating | 0 | 2 (6.9) |
Inappetence | 0 | 1 (3.4) |
Increased blood pressure | 1 (3.4) | 2 (6.9) |
Body pain | 1 (3.4) | 3 (10.3) |
Lab examinations within 3 days | ||
Increased alanine aminotransferase | 12 (41.4) | 11 (37.9) |
Hyperbilirubinemia | 2 (6.9) | 4 (13.8) |
Increased creatinine | 3 (10.3) | 2 (6.9) |
28-day mortality | ||
0 | 2 (6.9) | |
